KB-1365

LM305-hIgG1

33679

Background of LM305-hIgG1

LM-305 is composed of an anti-GPRC5D monoclonal antibody (mAb), coupled with a protease-degradable linker and a cytotoxic payload known as monomethyl auristatin E (MMAE). This innovative formulation positions LM-305 as a prospective first-in-class ADC (Antibody-Drug Conjugate) targeting GPRC5D. With its unique design and targeting specificity, LM-305 emerges as a promising therapeutic avenue. It signifies a potential breakthrough in offering a novel treatment modality for individuals contending with relapsed/refractory conditions.

Specifications

Catalog Number	KB-1365
Antibody Name	LM305-hIgG1
Isotype	Human IgG1,kappa
Target	GPRC5D
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells DOI: 10.1126/scitranslmed.aau7746.
Joshua Li, et al. The Molecule Pages database. Nature. 2002.